ValuEngine upgraded shares of Sienna Biopharmaceuticals (NASDAQ:SNNA) from a hold rating to a buy rating in a research report released on Thursday morning, ValuEngine reports.
Separately, JPMorgan Chase & Co. downgraded shares of Sienna Biopharmaceuticals from an overweight rating to a neutral rating in a research report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $21.67.
SNNA traded down $0.03 during trading on Thursday, hitting $0.80. 440 shares of the stock traded hands, compared to its average volume of 129,718. Sienna Biopharmaceuticals has a twelve month low of $0.72 and a twelve month high of $18.05. The firm has a market cap of $25.38 million, a P/E ratio of -0.22 and a beta of 2.90. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.61 and a current ratio of 2.61. The business’s 50 day moving average is $0.88.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.67) EPS for the quarter. On average, analysts forecast that Sienna Biopharmaceuticals will post -1.93 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in SNNA. Dimensional Fund Advisors LP acquired a new position in Sienna Biopharmaceuticals during the fourth quarter valued at approximately $36,000. LLBH Private Wealth Management LLC bought a new stake in shares of Sienna Biopharmaceuticals during the first quarter worth $49,000. Raymond James & Associates bought a new stake in shares of Sienna Biopharmaceuticals during the fourth quarter worth $54,000. Two Sigma Investments LP bought a new stake in shares of Sienna Biopharmaceuticals during the fourth quarter worth $149,000. Finally, Deutsche Bank AG grew its stake in shares of Sienna Biopharmaceuticals by 242.1% during the fourth quarter. Deutsche Bank AG now owns 104,718 shares of the company’s stock worth $241,000 after buying an additional 74,104 shares during the last quarter. Institutional investors and hedge funds own 51.32% of the company’s stock.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Story: Conference Calls
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.